Tyan Shin Lee

This case series demonstrates that secukinumab therapy for paediatric patients with congenital ichthyosis is safe and has variable efficacy, similar to results from clinical trials in adults. A good response is seen in patients with the erythrodermic phenotypes, namely congenital ichthyosiform erythroderma and Netherton syndrome, with a minor response seen in lamellar ichthyosis phenotypes. Clinical data are overall lacking for the paediatric population, and this study adds some insights to the existing research.

We described three patients with Netherton syndrome in Malaysia treated with secukinumab with variable outcomes. To date, there have only been reports of about eight patients being treated with secukinumab globally with this condition, with good outcomes. We hope our observation will add to the existing global pool of information about Netherton syndrome treated with secukinumab.